Nuvectis licenses Haisco's late-stage Factor B inhibitor and BRAF program in USD 1.4b deal

New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) has [signed an exclusive ex-China license agreement](https://www.globenewswire.com/news-release/2026/06/22/3315199/0/en/Nuvectis-Announces-Strategic-Portfolio-Expansion-via-License-Agreement-for-Ex-China-Rights-with-Haisco-Pharmaceutical-Group-for-Two-Potentially-Best-In-Class-Clinical-Stage-Compoun.html) with China-based Haisco Pharmaceutical Group (SHE: 002653) for two clinical-stage compounds — a Complement Factor B inhibitor (NXP100) and a paradox-breaker BRAF inhibitor (NXP200) — in a deal that transforms Nuvectis from a single-asset oncology developer into a multi-asset clinical-stage company spanning complement biology and precision oncology. Prior to the transaction, Nuvectis's pipeline was centered on NXP900, an oral SRC/YES1 kinase inhibitor currently in Phase Ib development for advanced solid tumors. Under the deal terms, Haisco will receive upfront and near-term payments totaling up to USD 40 million, plus up to USD 1.421 billion in development, regulatory, and commercial milestone payments, and tiered royalties on future net sales. Nuvectis receives exclusive worldwide ex-China rights to both compounds; however, Haisco retains rights to NXP100 in India and certain Southeast Asian territories, making the geographic scope for that asset narrower than for NXP200. The agreement is subject to financing conditions requiring Nuvectis to demonstrate sufficient capital for development. Specific royalty rates and individual milestone breakdowns were not disclosed. [NXP100 (HSK39297)](https://app.allsci.com/clinical-trial/ASC-CT-0000000040948-1.0-1745700230) is a once-daily oral Complement Factor B inhibitor in late-stage development. In China, two Marketing Authorization Applications are under review with the National Medical Products Administration for paroxysmal nocturnal hemoglobinuria (PNH) — one in treatment-naive patients and one in patients who failed C5 inhibitor therapy. In a completed Phase III trial (NCT06799546), NXP100 demonstrated superiority over eculizumab on the primary endpoint, with 59.5% of patients achieving hemoglobin levels ≥12 g/dL without transfusion versus 8.3% on eculizumab. NXP100 has also completed a Phase II and is in an ongoing [Phase III study in IgA nephropathy](https://app.allsci.com/clinical-trial/ASC-CT-0000001137392-1.0-1770733547), and in an ongoing Phase II study in lupus nephritis. The only currently approved Complement Factor B inhibitor is Novartis's iptacopan (Fabhalta), which is administered twice daily; Novartis is [expanding Fabhalta into IgA nephropathy following a strong Phase III](https://allsci.com/news/novartis-set-to-expand-vanrafia-to-iga-nephropathy-after-strong-phase-iii/), making once-daily dosing a potential differentiator for NXP100 in the same indications. NXP200 (HSK42360) is an oral, brain-penetrant paradox-breaker BRAF inhibitor targeting both BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors. Unlike first-generation BRAF inhibitors such as dabrafenib and encorafenib, which can trigger paradoxical MAPK pathway activation, NXP200 is designed to suppress BRAF signaling without activating the pathway in normal cells. A second-generation salt formulation has demonstrated improved pharmacokinetics over the free-base formulation used in an earlier dose-escalation study, which reported response rates exceeding 40% in adult glioma and durable responses in non-small cell lung cancer, colorectal cancer, and papillary thyroid cancer. A Phase Ib study is ongoing in China. The transaction also marks Haisco's third major international licensing deal in roughly three months. The company previously signed a USD 745 million[ pain portfolio agreement with AbbVie](https://app.allsci.com/news/ASC-NR-0000002367467-1.0-1779381220) and a USD 3.05 billion [multi-program collaboration with Eli Lilly](https://app.allsci.com/news/ASC-NR-0000003834752-1.0-1781764466), reflecting an increasingly active out-licensing strategy. The Nuvectis agreement adds complement biology and precision oncology to that list and reinforces Haisco's emergence as a repeat source of clinical-stage assets for multinational partners. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/nuvectis-haisco-acquisition-acquires-late-stage)